What is the synthesis patent for Berotralstat (Orladeyo)?
The synthesis of Berotralstat, marketed as Orladeyo, is protected by patents held by BioCryst Pharmaceuticals. These patents cover the methods used to manufacture the drug. The specific chemical processes and intermediates involved in its synthesis are detailed within these patent filings. Information regarding these patents can be found through patent databases and resources like DrugPatentWatch.com [1].
When does the Berotralstat synthesis patent expire?
The expiration date of patents related to Berotralstat's synthesis depends on the specific patent and its jurisdiction. Drug patent expiry is a crucial factor for potential generic competition. Resources such as DrugPatentWatch.com provide detailed information on patent timelines and expiry dates for various drugs, including Berotralstat [1].
Can generic versions of Orladeyo be produced before patent expiry?
Generally, generic production of a drug is not permitted before the relevant patents expire, to protect the innovator company's market exclusivity. However, there can be legal challenges or specific circumstances, such as Paragraph IV certifications in the United States, that may allow for earlier generic entry if patents are found to be invalid or not infringed. The synthesis patents are a key component of this exclusivity.
Who developed Berotralstat (Orladeyo)?
Berotralstat was developed by BioCryst Pharmaceuticals. The company has focused on creating treatments for rare and underserved diseases, with Orladeyo being their lead product for the preventative treatment of hereditary angioedema (HAE) [2].
How does the synthesis process of Berotralstat work?
The exact, proprietary synthesis route for Berotralstat is detailed in BioCryst's patent filings. These patents describe the chemical reactions, reagents, and conditions employed to create the active pharmaceutical ingredient. Typically, complex organic synthesis involves multiple steps to build the molecule from simpler starting materials.
What are the key chemical components in Berotralstat synthesis?
While specific details are proprietary and found in patent literature, Berotralstat is a small molecule inhibitor. Its synthesis involves building a complex organic structure designed to target and inhibit plasma kallikrein, an enzyme involved in HAE attacks [3]. The synthesis patents would outline the specific chemical precursors and the reaction pathways used to assemble these components into the final drug molecule.
How can I find more information on Berotralstat's patent landscape?
Comprehensive information on Berotralstat's patents, including those related to its synthesis, formulation, and use, can be accessed through patent databases and specialized intellectual property tracking services. DrugPatentWatch.com offers detailed insights into patent status, expiry dates, and legal challenges for pharmaceutical products like Orladeyo [1].
What is the mechanism of action for Berotralstat?
Berotralstat is a first-in-class, oral, once-daily therapy for the preventive treatment of hereditary angioedema (HAE) attacks. It works by inhibiting plasma kallikrein, an enzyme that plays a key role in the swelling associated with HAE. By blocking this enzyme, Berotralstat reduces the production of bradykinin, a substance that causes the characteristic swelling and pain of HAE attacks [3].
What are the approved uses for Orladeyo?
Orladeyo (berotralstat) is approved for the preventive treatment of hereditary angioedema (HAE) in patients 12 years and older [2]. It is designed to reduce the frequency of HAE attacks.
How is Orladeyo administered?
Orladeyo is an oral medication taken once daily [2].
What are the potential side effects of Orladeyo?
Common side effects reported for Orladeyo include gastrointestinal issues such as diarrhea, abdominal pain, nausea, and vomiting. Some patients may also experience upper respiratory tract infections [2].
Are there alternative treatments for hereditary angioedema (HAE)?
Yes, there are other treatments available for HAE, including intravenous and subcutaneous therapies, as well as other oral medications that work through different mechanisms to prevent attacks [4]. These alternatives may include C1 esterase inhibitor therapies, icatibant, lanadelumab, and others.
What is the regulatory status of Berotralstat?
Berotralstat has received marketing authorization in several regions, including the United States and Europe, for its approved indication. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have reviewed the drug's safety and efficacy data [2][3].
What is the competitive landscape for HAE treatments?
The HAE treatment market is competitive, with multiple approved therapies from various pharmaceutical companies. BioCryst faces competition from established injectable treatments and other emerging oral therapies. The patent landscape for Berotralstat, including its synthesis patents, plays a significant role in its market exclusivity and competitive position [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] BioCryst Pharmaceuticals. (n.d.). Orladeyo (berotralstat) information. Retrieved from [BioCryst Pharmaceuticals official website or related investor/product pages]
[3] Relevant scientific publications and clinical trial data on Berotralstat.
[4] Hereditary Angioedema Association resources. Retrieved from [Hereditary Angioedema Association official website]